Pu D - Search Results

1

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies.

Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, Ma XL. Zhou YW, et al. Among authors: pu d. Signal Transduct Target Ther. 2021 Aug 26;6(1):317. doi: 10.1038/s41392-021-00733-x. Signal Transduct Target Ther. 2021. PMID: 34446699 Free PMC article. Review.

2

A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): "typical" or "atypical" ARDS?

Pu D, Zhai X, Zhou Y, Xie Y, Tang L, Yin L, Liu H, Li L. Pu D, et al. Ann Transl Med. 2022 Aug;10(16):908. doi: 10.21037/atm-22-3717. Ann Transl Med. 2022. PMID: 36111011 Free PMC article. Review.

3

Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.

Pu D, Xu Q, Zhou LY, Zhou YW, Liu JY, Ma XL. Pu D, et al. Thorac Cancer. 2021 Nov;12(21):2914-2923. doi: 10.1111/1759-7714.14152. Epub 2021 Sep 28. Thorac Cancer. 2021. PMID: 34581010 Free PMC article.

4

Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.

Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X. Zhou Y, et al. Among authors: pu d. Int Immunopharmacol. 2021 Feb;91:107296. doi: 10.1016/j.intimp.2020.107296. Epub 2020 Dec 23. Int Immunopharmacol. 2021. PMID: 33360368

5

First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.

Zhou YW, Long YX, Chen Y, Liu JY, Pu D, Huang JY, Bi F, Li Q, Gou HF, Qiu M. Zhou YW, et al. Among authors: pu d. Cancer Med. 2021 May;10(10):3388-3402. doi: 10.1002/cam4.3876. Epub 2021 May 3. Cancer Med. 2021. PMID: 33939281 Free PMC article.

6

Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.

Zhou YW, Li QF, Chen YY, Wang K, Pu D, Chen XR, Li CH, Jiang L, Wang Y, Li Q, Yang Y, Gou HF, Bi F, Liu JY, Chen Y, Qiu M. Zhou YW, et al. Among authors: pu d. Eur J Surg Oncol. 2022 Jul;48(7):1559-1566. doi: 10.1016/j.ejso.2022.01.023. Epub 2022 Jan 31. Eur J Surg Oncol. 2022. PMID: 35115213

7

Criteria for judging the immune markers of COVID-19 disease vaccines.

Lin N, Fu H, Pu D, Quan Y, Li Y, Yin X, Wei Y, Wang H, Ma X, Wei X. Lin N, et al. Among authors: pu d. MedComm (2020). 2021 Dec 31;3(1):1-12. doi: 10.1002/mco2.109. eCollection 2022 Jan. MedComm (2020). 2021. PMID: 35005708 Free PMC article.

8

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, Zhou Q. Pu D, et al. Medicine (Baltimore). 2020 Jan;99(5):e19013. doi: 10.1097/MD.0000000000019013. Medicine (Baltimore). 2020. PMID: 32000444 Free PMC article.

9

Clinical Characteristics and Outcome Between Gallbladder Squamous Cell Carcinoma and Adenocarcinoma: A Propensity Matched Analysis Based on the Surveillance, Epidemiology, and End Results Database.

Chen X, Zhou Y, Xu Q, Pu D, Shu X, Wei G, Qiu M. Chen X, et al. Among authors: pu d. Front Oncol. 2022 May 2;12:833447. doi: 10.3389/fonc.2022.833447. eCollection 2022. Front Oncol. 2022. PMID: 35586486 Free PMC article.

10

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer.

Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, Li Y, Zhou Q, Li L. Pu D, et al. Front Oncol. 2021 Feb 26;11:637504. doi: 10.3389/fonc.2021.637504. eCollection 2021. Front Oncol. 2021. PMID: 33718229 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

457 results

Search Page